bioRxivCancer BiologyPreprint
Mapping chromatin state and transcriptional response in CIC-DUX4 undifferentiated round cell sarcoma
N. Thomas, C. Luck, N. Shlimon, R. Kriska Ponce, Z. Kosibaty, R. Okimoto
Abstract
CIC-DUX4 is a rare and understudied transcription factor fusion oncoprotein. CIC-DUX4 co-opts native gene targets to drive a lethal form of human sarcoma. The molecular underpinnings that lead to oncogenic reprograming and CIC-DUX4 sarcomagenesis remain largely undefined. Through an integrative ChIP and RNA-Seq analysis using patient-derived CIC-DUX4 cells, we define CIC-DUX4 mediated chromatin states and function. We show that CIC-DUX4 primarily localizes to proximal and distal cis-regulatory elements where it associates with active histone marks. Our findings nominate key signaling pathways and molecular targets that enable CIC-DUX4 to mediate tumor cell survival. Collectively, our data demonstrate how the CIC-DUX4 fusion oncoprotein impacts chromatin state and transcriptional responses to drive an oncogenic program in undifferentiated sarcoma. SignificanceCIC-DUX4 sarcoma is a rare and lethal sarcoma that affects children, adolescent young adults, and adults. CIC-DUX4 sarcoma is associated with rapid metastatic dissemination and relative insensitivity to chemotherapy. There are no current standard-of-care therapies for CIC-DUX4 sarcoma leading to universally poor outcomes for patients. Through a deep mechanistic understanding of how the CIC-DUX4 fusion oncoprotein reprograms chromatin state and function, we aim to improve outcomes for CIC-DUX4 patients.
- organism: human
- assay: ChIP-seq
- assay: bulk RNA-seq
- research focus: chromatin & epigenetic regulation
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The CIC-DUX4 fusion oncoprotein drives metastasis and tumor growth via distinct downstream regulatory programs and therapeutic targets in sarcoma
R. A. Okimoto, W. Wu, … T. G. Bivona·bioRxiv·Nov 21, 2018
- Expression of the CIC-DUX4 fusion oncoprotein mimics human CIC-rearranged sarcoma in genetically engineered mouse models
P. G. Hendrickson, K. M. Oristian, … D. G. Kirsch·bioRxiv·Sep 26, 2023
- WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma.
R. K. Ponce, N. J. Thomas, … R. A. Okimoto·bioRxiv·Jun 21, 2021
- The Capicua C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein
Cuyler Luck, Kyle A. Jacobs, Ross A. Okimoto·Cancer Research CommunicationsPeer-reviewed·Nov 12, 2024
- CIC-DUX4 expression drives the development of small round cell sarcoma in transgenic zebrafish: a new model revealing a role for ETV4 in CIC-mediated sarcomagenesis
S. Watson, G. C. Kendall, … J. F. Amatruda·bioRxiv·Jan 12, 2019
- Disruption of oncogenic targeting by ISWI via phosphorylation of a prion-like domain
M. Chen, J. P. Foster, … D. G. Kirsch·bioRxiv·Mar 11, 2020